Kornimate/medical-research-clean huggingface dataset:
path clinical data research network (cdrn) idiopathic pulmonary fibrosis (ipf) clinician patient partnership cohort

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the purpose of the path network ipf clinician-patient partnership cohort is to use clinical data from electronic health records (ehr) and patient reported outcomes (pro) to answer questions of clinical importance to patients with idiopathic pulmonary fibrosis, providers, and other stakeholders.

the primary objective is to create the path network ipf clinician-patient partnership cohort, which will allow the conduct of patient-centered observational studies on ipf across the multiple institutions (hershey penn state, university of pittsburgh, temple university) of the path network. creating the ipf clinician-patient partnership cohort will involve: 1. recruiting patients with ipf to participate in the path network ipf clinician-patient partnership cohort 2. administering surveys to the ipf clinician-patient partnership cohort approximately every 3 months to collect patient reported outcomes (pros) 3. merging individual patient health record data into the ipf clinician-patient partnership cohort database 4. tracking whether the patient participant has biospecimens in a path site biorepository and prepare for possible sharing of biospecimens in future studies. 5. determining if an automated procedure for identifying duplicate patients across path institutions without the use of protected health information (phi) is valid compared to a manual matching procedure using phi. 6. identifying potential participants for future research studies. the secondary objectives are to use the path network ipf clinician-patient partnership cohort to answer patient-centered research questions including: 1. what is the prevalence of gastroesophageal reflux disease (gerd) in ipf, and what effect does gerd and its treatment have on ipf disease progression, quality of life, and survival? 2. what is the association of oxygen use with survival, quality of life, exercise tolerance, neurocognitive function, and dyspnea? 3. how often do ipf patients have advance directives, how often are advance directives documented in the electronic health record, and does having an advance directive influence how/where ipf patients die, their health care utilization, satisfaction with care, and quality of life?

Eligibility criteria:
inclusion criteria: * the target study population is adults identified as having ipf (through the path ipf computable phenotype algorithm or a local ipf registry). exclusion criteria: * age \<18 years * deceased * not proficient in english * has not had at least one outpatient encounter in the past 18 months at the path health system's pulmonary specialty clinic through which they are recruited * lung transplant * already enrolled in the path clinician-patient partnership cohort at another path institution
sautour phrc ir 2008

Conditions: Mycosis

Summary: fusarium are microscopic filamentous fungi that live as saprobiontics in outside environments. they are found in the soil, the air, in water and on numerous plants. the frequency of fusariosis is currently increasing and fusarium-related mycoses are the 3rd most frequent invasive mycoses. most cases have been reported in the united states, in france, in italy and in brazil. a few epidemiological studies have shown the role of water in the appearance of mycoses in highly immunodepressed patients. few studies have focused on the role of water in the transmission of mycoses in hospitals. the aim of this prospective study is to describe, in time and pace, the contamination by fusarium sp. in the water of two different hospitals (dijon, nancy), by taking into account factors such as seasons and major works (reconstruction of a hospital). in each hospital, one reconstruction site will be compared with a site not under reconstruction (control). water samples will be taken from the rooms of hospitalized patients.


Eligibility criteria:
inclusion criteria: all patients with new-onset fusariosis in the adult haematology, internal medicinie, digestive surgery and rheumatology departments exclusion criteria: none
covid-19 among egyptian health care providers

Conditions: COVID

Summary: the study aims to identify covid 19 knowledge, working conditions, perception of anxiety and stigma among egyptian health care providers as well as their predictors.


Eligibility criteria:
inclusion criteria: * health care providers include physicians, nurses, and health officers both medical and nursing subjects. exclusion criteria: * medical students
evaluate the utility of the prolung test as adjunctive to ct scan in the diagnosis of lung cancer

Conditions: Solitary Pulmonary Nodule; Multiple Pulmonary Nodules

Summary: a study to evaluate the utility of the prolung test as an adjunct to ct scan in the diagnosis of lung cancer.

this study will assess the stability of the prolung test classification algorithm when used as an adjunct to ct scan. this study will assess whether there are any potential safety concerns of the prolung test when used to evaluate patients with a positive ct scan for lung cancer.

Eligibility criteria:
inclusion criteria: * subject is male or female, age 18 or above. * if female, subject * is of non-childbearing potential meaning permanently sterile, or * is one year post-menopausal; or * is not pregnant as confirmed by negative urine pregnancy test and using adequate birth control at time of screening. * subject presents with one or more of the following clinical symptoms or suspicious radiological finding(s): * persistent cough * hoarseness * shortness of breath * sputum streaked with blood * fatigue * unexplained recent weight loss * recurrent pneumonia or bronchitis * chest pain * abnormal chest radiograph * subject has undergone a ct scan of the lungs within 44 days of measurement that indicates one or more non-calcified nodules (ncn) or lung masses suspicious for lung cancer. * subject is capable of understanding and agreeing to fulfill the requirements of this protocol. * subject has signed the irb/iec approved informed consent form. exclusion criteria: • subjects who meet one or more of the following criteria may not be enrolled in this study: * subject has a pacemaker or other implanted electronic device. * subject with diagnosed malignancy within the past 5 (five) years except for non-melanoma skin cancer. * subject with significant systemic diseases including uncontrolled diabetes, severe heart failure, uncontrolled hypertension, myocardial infarction and/or auto-immune conditions within the prior 3 (three) months. * subject taking systemic corticosteroid medication (except for inhaled) within 14 days prior to measurement session. * subject has had an invasive medical procedure that involves the thoracic cavity within 30 days prior to the measurement session. * subject who currently abuses alcohol or drugs. * subject presents with an anomalous physical or anatomical condition that precludes measurement. * subject will have undergone unusually strenuous exercise within 24 hours prior to measurement session. * subject who has, in the principal investigator's opinion, any medical condition or other circumstance that would prevent completion of this study or interfere with analysis of the study results. * subjects who have undergone radiation and chemotherapy treatment within the past 30 days. * subject receiving therapy for documented or suspected chest infection. * pregnant or lactating females.
radial artery dilation study: the effect of topical administration of nitroglycerin and lidocaine versus lidocaine alone of the radial artery diameter

Conditions: Healthy

Summary: the radial artery, which is located on the outer side of the forearm, can be used in interventional procedures, such as cardiac catheterization, to provide access to the arterial blood supply. in order to facilitate successful catheterization of the artery, a dilated artery and one free of arterial spasm is desirable. the proposed study will randomize twenty three healthy subjects in 2 visits to determine the effect of topical nitroglycerin on radial artery vasodilation. radial artery diameter will be measured with ultrasound at regular intervals up to two hours.

during the first study visit, as a dose-optimizing study, each subject will be randomly assigned to one of two dose-test arms to receive either 15mg or 30mg of nitroglycerin on one wrist and placebo on the other. radial artery diameter will be measured with ultrasound at regular intervals up to two hours. on the second study visit, the same participants will be randomly assigned to one of two combination-test arms to receive bilateral topical application of either 20mg or 40mg of lidocaine; the lidocaine will be applied in combination with 30mg of nitroglycerin on one wrist and in combination with placebo on the other wrist. measurements of radial artery diameter will be performed as in the first visit.

Eligibility criteria:
inclusion criteria: * willing and able to give written informed consent and comply with study requirements * patient who speak english exclusion criteria: * presence or history of liver, cardiovascular, rheumatologic, cancer or renal disease. * current treatment with any vasodilator therapy * systolic blood pressure of less than 90 mmhg * history of radial artery catheterization within the previous year * absence of radial artery blood flow in one or both arms * pregnancy. * active infection * staff members of the cardiac catheterization laboratory.

Keywords: to determine if topical nitroglycerin acts to vasodilate the radial artery by a direct local action, or by systemic vasodilation to determine if topical nitroglycerin dilates the radial artery in the presence of local anesthetic agents used in cardiac catheterization
evaluation of romosozumab vs. zoledronic acid effect in patients with spinal cord injury and low bone mineral density

Conditions: Osteoporosis Fracture; Spinal Cord Injuries

Summary: this is a randomized study to determine the effects of monthly romosozumab for one year or one-time zoledronic acid on bone mineral density (bmd) and biochemical markers of bone formation and resorption, in patients with spinal cord injury (sci) and low bmd.

this is a randomized open-label study to determine the effects of monthly romosozumab for 12 month or one-time zoledronic acid infusion on bone mineral density (bmd) and biochemical markers of bone formation and resorption, in patients with spinal cord injury (sci) and low bmd. patients: thirty women between 20-70 years of age with spinal cord injury and low bone mass (bmd t-score lower than -2.0 in at least one location: lumbar spine, femoral neck or total hip sites) will receive study medication. primary outcome: total hip bmd change during a one-year treatment period. secondary outcome: change in femoral neck bmd at 12 months, bone turnover markers change over time (3, 9 and 12 month): c-terminal telopeptide of type i collagen (ctx), n-terminal propeptide of type i procollagen (p1np). study population: thirty women between 20-70 years of age with spinal cord injury that occurred more than 24 month ago and low bone mass (bmd t-score lower than -2.0 in at least one location: lumbar spine, femoral neck or total hip sites)

Eligibility criteria:
inclusion criteria: * bmd t-score ≤ -2.0 at the lumbar spine, total hip or femoral neck * sci of at least 24-month but less than 7 years duration, * american spinal injury association (asia) impairment scale a-c exclusion criteria: * myocardial infarction (mi) or stroke within the preceding year * high cardiovascular risk, 10 years framingham score over 20 %.

Keywords: bone mineral density fracture romosozumab
effect of pda closure on the left ventricular remodeling

Conditions: Congenital Heart Defect; Patent Ductus Arteriosus

Summary: failure of closure of the ductus arteriosus after birth results in a congenital anomaly known as patent ductus arteriosus. the large ductus can induce left side heart remodeling changes which could interfere with the normal cardiac function.

patent ductus arteriosus (pda) is a congenital heart disease that represents 6-11% of all congenital heart diseases and is due to failure of spontaneous closure of a normal foetal duct called ductus arteriosus, that is a duct connecting the left pulmonary artery to the aorta, and it may result in lv volume overload , pulmonary overflow that may end with development of eisenmenger syndrome. lv volume overload of the big ductus induce left heart remodeling changes in form of la and lv dilatation, and lv hypertrophy to compensate for the increased wall stress. some patients compensate well and remain asymptomatic, while others can't and develop manifestations of lv systolic dysfunction . traditional echocardiography is the main diagnostic tool for the pda and assessment of its hemodynamic effect on the heart. speckle tracking echocardiography ( ste) is a relatively novel tool that can assess the lv function by tracking the speckles of the grey scale 2d images. recent studies revealed good correlation between the lvef measured by traditional echocardiography and global longitudinal strain (gls) measured by ste , in addition to detection of subtle myocardial dysfunction by ste in patients with heart failure with preserved lvef before frank lv systolic dysfunction is apparent clinically . pda closure should induce reverse remodelling with improvement of the left heart dimensions and function . many studies in pediatrics showed deterioration of lvef early after pda closure followed by rapid recovery , while fewer studies showed late improvement of the lvef in the adults .

Eligibility criteria:
inclusion criteria: * all patients who are candidate for transcatheter pda closure. exclusion criteria: 1. patients with pda dependent pulmonary circulation. 2. patients with small sized pda which is silent by auscultation. 3. patients with large sized pda which is unsuitable for trans-catheter closure . 4. patients with pda and severe irreversible pulmonary hypertension (eisenmenger's syndrome) (7). 5. patients with active infection or active infective endarteritis. 6. patients refusing the study. 7. patients with dm, htn and ischemic heart diseases. 8. patients with associated congenital or acquired cardiac lesions that may interfere with lv mechanics.
optimized 2d-rt for prostate cancer

Conditions: Prostate Cancer

Summary: prostate cancer (cap) is one of the most common malignancies in men, both in western countries and developing countries. radiation therapy (rt) is an important therapeutic option. new technologies (3d, imrt, igrt, vmat) have been introduced in the last decades, with a progressive improvement of clinical outcome. however, in many countries the only treatment option is the traditional 2d technique based on standard simulation. the indications for field definition in this treatment are still based on expert's opinions. the aim of this analysis is to propose new indications for 2d fields definition based on three-dimensional simulation in a population of patients with cap. twenty patients with cap consecutively treated with rt in our center were identified. patients underwent ct-simulation in supine position. pelvic mri images were fused with ct-simulation images. in this way, delineation of the prostate and seminal vesicles was performed on mri images. clinical target volume definition (ctv) was performed according to eortc guidelines simulating 4 different categories: low-risk cap, intermediate-risk cap, high-risk cap without involvement of the seminal vesicles, and high-risk cap with involvement of seminal vesicles. the planning target volume (ptv) was defined by adding a margin of 10 mm to the ctv in all directions. for each patient, 8 treatment plans were calculated. in particular, for each of the 4 categories of risk, 2 treatment plans were calculated by using a cobalt source or 10 mv photons. treatment plans were calculated using the box technique. progressive optimization was realized with an iterative procedure by evaluating the three-dimensional dose distribution. once the final plan was achieved (respecting the ptv constraint: d98 \> 95%), distances of the fields edges from a set of reference points were measured.


Eligibility criteria:
inclusion criteria: * \> 18 years * clinical t stage: ct2b, ct2c, ct3a, ct3b * informed consent * mri of the pelvis exclusion criteria: * \> 79 years * prior surgery treatment for prostate cancer * prior pelvic radiotherapy * genetic syndromes of hyper-radio-sensitivity * chronic infiammatory bowel disease

Keywords: 2d prostate neoplasms radiotherapy simulation
trial of pregabalin for post-operative pain in women undergoing abdominal hysterectomy

Conditions: Postoperative Pain; Opioid Use

Summary: we hypothesize that pregabalin will decrease post-operative pain scores and opioid use following abdominal hysterectomy compared to placebo. this study has been designed to determine if after an abdominal hysterectomy, the addition of pregabalin to their peri-operative analgesia regimen will demonstrate superior analgesia compared to placebo in terms of lower pain scores and reduced usage of opioids. the primary outcome will be post-operative pain, measured by total opioid consumption. do women undergoing an abdominal hysterectomy with general anesthesia and receiving pregabalin prior to their surgery and 12 hours later have lower opioid consumption in the first 24 hours after their surgery than those women who received placebo?


Eligibility criteria:
inclusion criteria: 1. american society of anesthesia physical status class i \& ii 2. age \> 18 years 3. english-speaking 4. capability to operate a patient-controlled analgesia (pca) device exclusion criteria: 1. known or suspected allergy, sensitivity, or contraindication to pregabalin or any of the standardized medications (i.e. morphine, anesthetic agents) 2. morbid obesity (body mass index ≥ 45 kg/m2) 3. history of a seizure disorder 4. current therapy with pregabalin, gabapentin, or any opioid 5. any other physical or psychiatric condition which may impair their ability to cooperate with post-operative study data collection 6. crcl \< 60 ml/min \[crcl = 0.85 x ((140 - age) x weight(kg)) / (72 x cr(mg/dl)))\]
single and repeat dose pharmacokinetic study of gsk1605786 in healthy chinese subjects

Conditions: Crohn's Disease

Summary: this is an open-label, parallel group, single and repeat dose pharmacokinetic (pk) study in healthy male and female subjects. this study will confirm the pk and safety profile in chinese subjects. gsk1605786 is currently in clinical development for the treatment of crohn's disease. subjects will receive one of two gsk1605786 doses (500 mg once daily or 500mg twice daily) within 30 minutes after a meal. the study will consist of single and repeat dose sessions, with pre-dose and serial pk samples taken up to 72-h post-dose.


Eligibility criteria:
inclusion criteria: * healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ecg * male or female between 18 and 45 years of age * body weight 50 kg (110lbs) for men and women, and body mass index (bmi) within the range 19 24 kg/m2 exclusion criteria: * a positive pre-study hepatitis b surface antigen or positive hepatitis c antibody result within 3 months of screening * current or chronic history of liver disease, or known hepatic or biliary * a positive test for hiv antibody at screening * known coeliac disease and positive serologic testing for anti-ttg antibodies * a positive pre-study drug/alcohol screen * lactating females

Keywords: healthy gsk1605786 ccr9 receptor antagonist chinese subjects pharmacokinetics
motiva flora® aesthetic breast recon® clinical study

Conditions: Mammaplasty; Breast Cancer; Poland Syndrome

Summary: the present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the motiva flora® tissue expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant ergonomix2®.


Eligibility criteria:
inclusion criteria: 1. genetically female, aged 18 years or older. 2. subjects who had provided written informed consent form. 3. the participant needs tissue expansion as part of breast reconstruction treatment, which may include immediate reconstruction. 4. clinical condition to allow reverse expansion breast reconstruction, at the investigator's discretion. 5. sufficient fat in donor sites (abdomen, gluteus, hips, and thighs) per plastic surgeon criteria. 6. complete radiotherapy and chemotherapy at least one year before surgery. 7. bmi between 18.5 and 30.0 (average classified weight). 8. physical and cognitive capacity to understand and follow the surgeon's recommendations. 9. to be able and willing to comply with all study requirements, including attending follow-up appointments. only sub study participants 10. provide additional consent to undergo an mri with contrast. exclusion criteria: 1. current pregnancy or lactation, or full-term pregnancy or lactation at any point during the clinical investigation. 2. abnormal hematological and biochemical values after chemotherapy. 3. high surgical risk according to the investigator. 4. breast width larger than 18 cm 5. tumor residues in or near the area where tissue expansion is performed. 6. subjects with metastatic breast cancer 7. significant breast ptosis or poor skin quality 8. participants who do not have adequate tissue at the intended site for expansion, at the surgeon's discretion, due to previous radiotherapy, ulceration, vascular involvement, history of impaired wound healing, or mastectomy scar deformity. 9. inadequate chest wall tissue due to damage caused by radiotherapy, tight skin grafts, or radical resection of the pectoralis major muscle. 10. current or previous infection in the area where the expansion occurs. 11. any condition that impedes magnetic resonance imaging (mri), including implanted metal device, claustrophobia, or other ailments that would prohibit mri scan. 12. presence of autoimmune diseases such as lupus or scleroderma, or immunocompromised participants due to immunosuppressive or steroid therapy. 13. history of silicone sensitivity. 14. active smokers 15. previous attempts of breast reconstruction 16. subjects who, in the opinion of the investigator, are considered part of any vulnerable population 17. subjects with affiliation to the sponsor, sites or investigators, including relatives. 18. participants who do not live in the procedure's country make it impossible to assist in follow-up visits. 19. subjects who are participating in other investigation(s) which may affect the outcomes or ability to comply follow-up requirements of this study

Keywords: reverse expansion aesthetic breastrecon™ hybrid breast reconstruction implant autologous tissue
cow milk allergy: evaluation of the efficacy of a new thickened extensively hydrolyzed formula in infants with confirmed cow milk allergy

Conditions: Cow Milk Allergy

Summary: the aim of the study is to assess the hypoallergenicity of a new thickened extensively hydrolyzed formula.


Eligibility criteria:
inclusion criteria: * between 1 and 12 months old * having a cow milk allergy confirmed by a positive double-blind food challenge performed in the last 3 months, * whose parent(s) signed the informed consent form exclusion criteria: * infants mainly or exclusively breastfed, * infants having a weight at inclusion \< 2500g, * infants who refused to drink an extensively hydrolyzed formula anytime prior to inclusion, * infants fed an amino acid based formula * infants who had an anaphylactic reaction in the past,